The Use of Bioquantine® and Allogeneic Mesenchymal Stem Cells..
Combined with a Spinal Cord Stimulation System in a No Option Patient with ASIA-A Scale
In 1973 the American Spinal Injury Association made the International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI). In this clinical review our patient was classified after the vertebral fixation surgery with a ASIA-A scale injury after suffering a fracture and luxation at T-12-L1, having total spinal cord section (Figure A).
Based on the research made by Sergei Paylian PhD on animal models  and the safety use of allogeneic MSCs demonstrated on multiple animal models applications [2,3], we decided to apply an experimental translational medical protocol based the research and the previous outcomes obtained by Hamid and MacEwan [4,5] and decided to customize it exclusively to our patient based on the clinical evidence and personalizing the therapy on evidence. The medical team designed an ambulatory method utilizing a C-arm to apply the allogeneic MSCs in situ and using a intrathecal (subdural) catheter using a slow pump release system for the rest of the biological material with an optimum tolerance and minor side effects (mild fever, myalgias and headache) on the first 48 hrs hour after application. The experimental use of mRNA Bioquantine® was well tolerated with its purified form (intra and extra-oocyte liquid phases of electroporated oocytes ) showing to be well tolerated by the patient without any anaphylactic reaction. The current clinical report is meant to demonstrate the beneficial changes with the use of Bioquantine® and its administration in a patient with a severe SCI offering a possible optional therapy and potential neuroregeneration in this clinical condition.